Boggon, Titus J.

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 9,368

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 3,964

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell

Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 2,993

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 1,224

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 1,192

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., et al. (2012) · Nature Genetics

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 1,191

Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth

Hitosugi, T., Kang, S., Vander Heiden, M. G., Chung, T.-W., Elf, S., Lythgoe, K., Dong, S., Lonial, S., Wang, X., Chen, G. Z., et al. (2009) · Science Signaling

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 784

Structure and regulation of Src family kinases

Boggon, T. J., & Eck, M. J. (2004) · Oncogene

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 712

Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex

Fan, J., Shan, C., Kang, H.-B., Elf, S., Xie, J., Tucker, M., Gu, T.-L., Aguiar, M., Lonning, S., Chen, H., et al. (2014) · Molecular Cell

Biochemical Acid Research StudiesCancer, Hypoxia, and Metabolism

Cited by 305

6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1–AMPK signalling

Lin, R., Elf, S., Shan, C., Kang, H.-B., Ji, Q., Zhou, L., Hitosugi, T., Zhang, L., Zhang, S., Seo, J. H., et al. (2015) · Nature Cell Biology

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 287

EGFR-mutated lung cancer: a paradigm of molecular oncology

Zhang, Z., Stiegler, A. L., Boggon, T. J., Kobayashi, S., & Halmos, B. (2010) · Oncotarget

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 197

MAST1 drives cisplatin resistance in human cancers by rewiring cRaf-independent MEK activation

Jin, L., Chun, J., Pan, C., Li, D., Lin, R., Alesi, G. N., Wang, X., Kang, H.-B., Song, L., Wang, D., et al. (2018) · Cancer Cell

Melanoma and MAPK PathwaysMetal complexes synthesis and properties

Cited by 132

Tetrameric acetyl-CoA acetyltransferase 1 is important for tumor growth

Fan, J., Lin, R., Xia, S., Chen, D., Elf, S. E., Liu, S., Pan, Y., Xu, H., Qian, Z., Wang, M., et al. (2016) · Molecular Cell

Cancer, Hypoxia, and MetabolismBiochemical Acid Research Studies

Cited by 106

Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patients

Le Coz, C., Nguyen, D. N., Su, C., Nolan, B. E., Albrecht, A. V., Xhani, S., Sun, D., Demaree, B., Pillarisetti, P., Khanna, C., et al. (2021) · Journal of Experimental Medicine

Immunodeficiency and Autoimmune DisordersGenomics and Chromatin Dynamics

Cited by 69

The C2 domain augments Ras GTPase-activating protein catalytic activity

Paul, M. E., Chen, D., Vish, K. J., Lartey, N. L., Hughes, E., Freeman, Z. T., Saunders, T. L., Stiegler, A. L., King, P. D., & Boggon, T. J. (2025) · Proceedings of the National Academy of Sciences

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 7